An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Ligelizumab (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Sponsors Novartis
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2017 Planned End Date changed from 1 May 2019 to 13 Jun 2019.
- 02 Aug 2017 Planned primary completion date changed from 1 May 2019 to 13 Jun 2019.